ArriVent BioPharma (NASDAQ: AVBP) presents phase 1b lung cancer data

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. filed a report describing a new corporate update related to its lung cancer drug development work. The company issued a press release announcing that it presented the final analysis of firmonertinib monotherapy data from its global phase 1b study in EGFR PACC mutant non-small cell lung cancer at the 2025 World Conference on Lung Cancer.

The press release is included as Exhibit 99.1 and most of its contents are incorporated by reference into this report, while being furnished rather than filed for securities law purposes.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/09/2025 - 08:00 AM Learn about SEC filing dates

FAQ

What did ArriVent BioPharma (AVBP) disclose in this Form 8-K?

ArriVent BioPharma reported that it issued a press release announcing the presentation of final firmonertinib monotherapy data from a global phase 1b study in EGFR PACC mutant non-small cell lung cancer at the 2025 World Conference on Lung Cancer.

What clinical program is highlighted for ArriVent BioPharma (AVBP)?

The update highlights firmonertinib monotherapy from a global phase 1b study in patients with EGFR PACC mutant non-small cell lung cancer.

Where were ArriVent BioPharma's firmonertinib data presented?

The company presented the final analysis of its firmonertinib monotherapy phase 1b data at the 2025 World Conference on Lung Cancer.

How is the ArriVent BioPharma press release treated under securities laws?

The information in Item 7.01, including the press release, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act or automatically incorporated into other filings, except where specifically referenced.

Which exhibit in the ArriVent BioPharma 8-K contains the press release?

Exhibit 99.1 to the report contains the press release dated September 9, 2025, describing the firmonertinib data presentation.

Who signed this ArriVent BioPharma Form 8-K?

The report was signed on behalf of ArriVent BioPharma, Inc. by Winston Kung, the company’s Chief Financial Officer and Treasurer.

0001868279false00018682792025-09-092025-09-09

​

​

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): September 9, 2025

​

ARRIVENT BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

​

Delaware		001-41929		86-3336099
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

​ ​
18 Campus Boulevard, Suite 100 Newtown Square, PA		19073
(Address of principal executive offices)		(zip code)

​

Registrant’s telephone number, including area code: (628) 277-4836

​

N/A 

(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		AVBP		The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

​

Emerging Growth Company ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 7.01 Regulation FD Disclosure.

​

On September 9, 2025, ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing that the Company presented the final analysis of firmonertinib monotherapy data from its global phase 1b study in EGFR PACC mutant non-small cell lung cancer at the 2025 World Conference on Lung Cancer. A copy of the press release is filed as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 7.01.

​

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

​

Item 8.01 Other Events.

​

The information set forth in the press release referred to in Item 7.01 above, other than the second paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

​

Item 9.01Financial Statements and Exhibits.

​

(d) Exhibits.

Exhibit No.		Description
99.1	​	Press Release dated September 9, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ARRIVENT BIOPHARMA, INC.
	By:	/s/ Winston Kung
		Winston Kung
		Chief Financial Officer and Treasurer

​

Date: September 9, 2025

​

​

​